drugset
drugset / Trial / NCT03744208

SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma

NCT03744208 ↗

Phase 2 Unknown 30 enrolled Shi Yuankai
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of first-line with recombinant anti-EGFR monoclonal antibody（SCT200）and standard chemotherapy in patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.

Timeline

Start
2018-12-30
Primary completion
2019-12-31
Completion
2020-05-28

Drugs

EvaluationDrugModalityDoseRoute
Subject SCT200 Monoclonal antibody 8 mg/kg —
Background DDP Unknown 75 mg/m2 —
Background fluorouracil Small molecule 750 mg/m2 —

Indications

head and neck squamous cell carcinoma